Acylcarnitines profile best predicts survival in horses with atypical myopathy

François Boemer (1) , Johann Detilleux (2) , Christophe Cello (3) , Hélène Amory (2) , Christel Marcillaud-Pitel (4) , Eric Richard (5, 6) , Gaby van Galen (2) , Gunther van Loon (7) , Laurence Lefère (7) , Dominique-Marie Votion (2)

1 CHU-Liège - Centre Hospitalier Universitaire de Liège
2 Faculté de Médecine Vétérinaire [Liège]
3 Université de Liège
4 RESPE - Réseau d'Epidémio-Surveillance en Pathologie Équine
5 LABÉO - LABÉO, Pôle d’analyses et de recherche de Normandie
6 BIOTARGEN - Biologie, génétique et thérapies ostéoarticulaires et respiratoires
7 UGENT - Universiteit Gent = Ghent University

Equine atypical myopathy (AM) is caused by hypoglycin A intoxication and is characterized by a high fatality rate. Predictive estimation of survival in AM horses is necessary to prevent unnecessary suffering of animals that are unlikely to survive and to focus supportive therapy on horses with a possible favourable prognosis of survival. We hypothesized that outcome may be predicted early in the course of disease based on the assumption that the acylcarnitine profile reflects the derangement of muscle energetics. We developed a statistical model to prognosticate the risk of death of diseased animals and found that estimation of outcome may be drawn from three acylcarnitines (C2, C10:2 and C18 -carnitines) with a high sensitivity and specificity. The calculation of the prognosis of survival makes it possible to distinguish the horses that will survive from those that will die despite severe signs of acute rhabdomyolysis in both groups.

Domaines: Médecine vétérinaire et santé animale

François Boemer, Johann Detilleux, Christophe Cello, Hélène Amory, Christel Marcillaud-Pitel, et al.. Acylcarnitines profile best predicts survival in horses with atypical myopathy. PLoS ONE, 2017, 12 (8), pp.e0182761. ⟨10.1371/journal.pone.0182761⟩. ⟨hal-02167888⟩